1 Inhibitor screening of Spike variants reveals the heterogeneity

2 of neutralizing antibodies to COVID-19 infection and

3 vaccination

4 Xiaomei Zhang^{1,8}, Mei Zheng^{2,3,5,8}, Te Liang^{1,8}, Haijian Zhou^{4,5,8}, Hongye

- 5 Wang¹, Jiahui Zhang¹, Jing Ren¹, Huoying Peng¹, Siping Li¹, Haodong Bian¹,
- 6 Chundi Wei¹, Shangqi Yin^{2,3,5}, Chaonan He^{2,3,5}. Ying Han^{2,3,5}, Minghui Li^{4,5},
- 7 Xuexin Hou^{4,5}, Jie Zhang⁶, Liangzhi Xie⁶, Jing Lv⁷, Biao Kan^{4,5,9}, Yajie
- 8 Wang^{2,3,5,9}, Xiaobo Yu^{1,9}
- 9

10 **Affiliations**

- ¹¹ State Key Laboratory of Proteomics, Beijing Proteome Research Center,
- 12 National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing
- 13 Institute of Lifeomics, Beijing, 102206, China.
- ² Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical
 University, Beijing, China.
- ³ Department of Research Ward, Beijing Ditan Hospital, Capital Medical
- 17 University, Beijing, China.
- ⁴ State Key Laboratory of Infectious Disease Prevention and Control, National
- 19 Institute for Communicable Disease Control and Prevention, Chinese Center
- ²⁰ for Disease Control and Prevention, Beijing, 102206, China
- ⁵ Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital,
- 22 Beijing, 102206, China

- ⁶ Beijing Key Laboratory of Monoclonal Antibody Research and Development,
- Sino Biological, Inc., Beijing, 100176, China
- ⁷ Gobond Testing Technology (Beijing) Co., Ltd., Beijing, 102629, China.
- 26
- ⁸ These authors contributed equally to this work.
- ⁹Correspondence: xiaobo.yu@hotmail.com (X. Y.), wangyajie@ccmu.edu.cn
- 29 (Y. W.), kanbiao@icdc.cn (B. K.)
- 30

31 Highlights

- Developed a high throughput assay to screen the neutralizing effect of
- antibodies across multiple SARS-CoV-2 Spike variants simultaneously.
- Characterized the heterogeneity of neutralizing antibodies produced in
- response to COVID-19 infection and vaccination.
- Demonstrated the capacity of Spike variants neutralization is associated
 with the diversity of anti-Spike antibodies.
- 38

39 Abstract

40 Mutations of the coronavirus responsible for coronavirus disease 2019 41 (COVID-19) could impede drug development and reduce the efficacy of 42 COVID-19 vaccines. Here, we developed a multiplexed Spike-ACE2 Inhibitor 43 Screening (mSAIS) assay that can measure the neutralizing effect of 44 antibodies across numerous variants of the coronavirus's Spike (S) protein

45	simultaneously. By screening purified antibodies and serum from convalescent
46	COVID-19 patients and vaccinees against 72 S variants with the mSAIS assay,
47	we identified new S mutations that are sensitive and resistant to neutralization.
48	Serum from both infected and vaccinated groups with a high titer of
49	neutralizing antibodies (NAbs) displayed a broader capacity to neutralize S
50	variants than serum with low titer NAbs. These data were validated using
51	serum from a large vaccinated cohort (n=104) with a tiled S peptide microarray.
52	In addition, similar results were obtained using a SARS-CoV-2 pseudovirus
53	neutralization assay specific for wild-type S and four prevalent S variants
54	(D614G, B.1.1.7, B.1.351, P.1), thus demonstrating that high antibody diversity
55	is associated with high NAb titers. Our results demonstrate the utility of the
56	mSAIS platform in screening NAbs. Moreover, we show that heterogeneous
57	antibody populations provide a more protective effect against S variants, which
58	may help direct COVID-19 vaccine and drug development.

59

60 Keywords

SARS-CoV-2, COVID-19, microarray, neutralizing antibody, mutation, Spike
 62

63 Introduction

Coronavirus disease 2019 (COVID-19) is caused by the severe respiratory
coronavirus 2 (SARS-CoV-2). As of May 2021, SARS-CoV-2 had infected 162
million people and caused over three million deaths worldwide (Dong et al.,

67 2020). A key step in infection is viral entry, which is facilitated by the interaction between the SARS-CoV-2 Spike (S) protein via its receptor binding domain 68 69 (RBD) (319 – 541 aa) with the human Angiotensin-Converting Enzyme 2 70 (ACE2) receptor. Thus, this interaction is a major focus in drug and vaccine 71 development efforts (Burki, 2021; Dai and Gao, 2021). For example, the current COVID-19 vaccines approved by the U.S. Food and Drug 72 Administration (FDA) stimulate the immune response to generate antibodies 73 neutralizing the Spike-ACE2 interaction. 74 capable of Unfortunately, 75 SARS-CoV-2 is mutating, with new variants emerging nearly every week that 76 could impede drug development and reduce the efficacy of COVID-19 vaccines (Dai and Gao, 2021; Kemp et al., 2021). 77

78 Mutations in the S protein are of particular concern since they could 79 enable SARS-CoV-2 to evade defense mechanisms that are elicited by 80 COVID-19 vaccines and therapeutic antibodies (Aschwanden, 2021; Del Rio and Malani, 2021). For example, the D614G variant, which was first identified 81 in July 2020, has a faster infection rate and higher viral load in the upper 82 respiratory tract than the wild-type "Wuhan-Hu-1" strain (Hou et al., 2020b; 83 Korber et al., 2020). It has since become one the most prevalent strains. The 84 85 B.1.1.7 variant (D614G, N501Y) is more infectious and may lead to increased 86 mortality compared to the parental strain (Davies et al., 2021; Galloway et al., 87 2021). The B.1.351 and P.1 variants contain three RBD mutations at E484K, N501Y, and K417N or K417T, respectively. These mutations have shown 88

89 resistance to neutralizing antibodies (NAbs) produced by convalescent COVID-19 patients and vaccinees that inhibit the wild-type Spike-ACE2 90 91 interaction (Garcia-Beltran et al., 2021; Liu et al., 2021; Madhi et al., 2021; Wang et al., 2021a; Wang et al., 2021b; Wibmer et al., 2021). The vaccinees in 92 these studies received the most popular vaccines worldwide, including 93 mRNA-based COVID-19 vaccines (Moderna and Pfizer BioNTech) and a 94 replication-deficient chimpanzee adenoviral vector COVID-19 vaccine 95 (AstraZeneca). Similar results were obtained when testing a B.1.1.7 variant 96 with an additional E484K mutation (Collier et al., 2021; Wang et al., 2021b). 97 These studies highlight the importance of an assay that can measure the 98 99 humoral response to S variants in developing effective therapeutic antibodies 100 and vaccines for COVID-19 (Burki, 2021; Priesemann et al., 2021).

101 To address this urgent need, we developed a protein microarray for the 102 high throughput, multiplexed detection of NAbs to SARS-CoV-2 S variants. 103 This multiplexed Spike-ACE2 Inhibitor Screening (mSAIS) assay is simple to use, able to detect NAbs to numerous S variants simultaneously, requires 104 105 minimal sample volume (i.e., 20 µL serum), and can be performed with 106 common laboratory equipment. It could also be used with other potential 107 neutralizing molecules (e.g., small molecules). To demonstrate the potential of 108 the mSAIS assay, we assessed the neutralization potential of purified anti-S 109 antibodies and serum from convalescent COVID-19 patients and vaccinees across 72 S variants. The sensitivity and resistance of the various S protein 110

mutations to the NAbs were determined, and new escape mutations that are not targeted by vaccine-induced antibodies were identified. The neutralization capacity of high and low titer NAb titer samples was also compared. Our results were validated using a peptide-based microarray and SARS-CoV-2 pseudovirus neutralization assay.

116

117 **Results**

Development of the mSAIS assay.

The mSAIS assay enables the simultaneous screening of various potential 119 120 neutralizing molecules across numerous SARS-CoV-2 S variants within 2 121 hours (Figure 1A). Here, 72 S protein variants with a polyhistidine tag at the 122 C-terminus were expressed in the human embryonic kidney 293 (HEK293) cell 123 line (Figure S1), purified, and printed onto a chemically-modified glass slide as 124 previously described (Wang et al., 2020; Zhang et al., 2020b). The printed S 125 protein variants were selected from the COVID-19 virus mutation tracker database (Figure S2) and literature, and included 2 variants with mutations in 126 127 the S protein's subunit 1 (S1) and subunit 2 (S2) domains, 7 variants with 128 mutations in S1, and 63 variants with mutations in the RBD (Alam et al., 2021). 129 Prevalent SARS-CoV-2 strains, such as the D614G, B.1.1.7, and B.1.351 130 strains, were among the variants printed. In addition, two negative controls and 131 one positive control (SARS-CoV-2 wild-type RBD) were printed on the array (Figure S3). The negative controls included on the array were the 132

SARS-CoV-2 Nucleocapsid (N) protein and the RBD of the Middle East respiratory syndrome coronavirus 2 (MERS-CoV-2). Following printing, the sample (e.g., NAb) and a Cy5-labeled extracellular domain of ACE2 were sequentially incubated on the array with alternated wash steps to remove unbound sample and ACE2. Thus, S-ACE2 complex formation resulted in fluorescence whereas neutralizing samples decreased fluorescence.

139 Before using the mSAIS assay to screen samples, the reproducibility of the 140 array and the binding of the S variants with ACE2 in the presence and absence 141 of NAbs were evaluated. The results show that the intra- and inter-array r142 correlations for each step of the assay were 0.99 and 0.98, respectively 143 (Figure S4, Figure 1B and 1C). Furthermore, the neutralizing capacity of 13 144 serum samples from vaccinees determined by the mSAIS assay was 145 compared to the data obtained using the live SARS-CoV-2. The r correlation 146 between the two approaches was 0.82 (Figure S5), demonstrating that the 147 mSAIS assay has high reproducibility and is a feasible approach for screening 148 potential neutralizing molecules. It is also important to note that working with 149 live SARS-CoV-2 requires biosafety level 3 (BSL3) facilities whereas the 150 mSAIS assay can be performed safely at BSL1 or BSL2 depending on the 151 nature of the tested samples.

152

Characterizing ACE2 interactions with Spike variants with the mSAIS
 assay

155 By testing different amounts of purified antibodies or serum, the half maximal inhibitory concentration (IC50) or effective concentration (EC50) can be 156 157 determined, respectively, and the results visualized via fluorescence. When 158 the concentration of ACE2 applied to the assay was low (< 2.5 μ g/mL), the 159 fluorescent signal across the different S variants varied, thus indicating that the binding affinities of ACE2 to the S variants are not the same (Figure 2A). 160 Indeed, the calculation of the EC50 for the S variants with mutations between 161 162 residues 234 - 614 shows that the binding affinity (EC50) ranges from 0.65 to 163 17.25 µg/mL. ACE2 had the lowest binding affinity to two S variants, F465E 164 and N487R, with an EC50 of 16.16 and 17.25 µg/mL, respectively (Figure 2B). The EC50 ratios between the wild-type and variant S proteins were 165 166 calculated and log2 transformed (Figure 2C). Using a 2-fold minimum as the 167 selection criteria, 10 mutations that weaken the S-ACE2 interaction were 168 identified, including A372T, F377L, G446V, F456E, G485S, F486S, N487R, F490L, P499R and Y505C (Figure 2C and 2D). Notably, the S variant D614G 169 did not appear to affect ACE2 binding, which agrees with a previous study 170 171 using surface plasmon resonance (Zhang et al., 2020a). 172 Interestingly, 8/10 (80%) mutations that decreased the ability of the S

protein to bind ACE2 (G446V, F456E, G485S, F486S, N487R, F490L, P499R,
Y505C) are located at the RBD-ACE2 interaction interface (Figure 2E).
Moreover, F456E and N487R had the weakest ACE2 binding affinities. These
results further support the importance of the RBD domain in antibody

neutralization (Barnes et al., 2020; Dai and Gao, 2021; Tan et al., 2020).

178

179 Heterogeneous reaction of antibodies to Spike variants

Three antibodies that bind to the S protein's RBD (Figure S6) were tested with the mSAIS assay, including a mouse monoclonal antibody #73, a rabbit polyclonal antibody #21, and a rabbit monoclonal antibody #53 (Figure 3). The IC50 of antibodies #21 and #53 to the S variants range from 42.04 – 10,000 ng/mL and 0.00063 – 10,000 ng/mL, respectively (Figure 3B and 3C). However, antibody #73 did not inhibit the RBD-ACE2 interaction (Figure 3A), indicating that not all anti-RBD antibodies have neutralizing activity.

Antibody #21 was unable to neutralize the formation of the S-ACE2 187 complex for 8 "resistant" S variants: R408I, HV69-70 deletion/N501Y/D614G 188 189 (B.1.1.7 strain), G446V. F456E. N487R, F490L. Y505C. and 190 K417N/E484K/N501Y (B.1.351 strain) (Figure 3B). Two other studies also observed similar results for the B.1.351 strain (Li et al., 2021; Wang et al., 191 2021a). Using a two-fold difference in signal compared to the wild-type S 192 193 protein as the criteria, 33 variants showed resistance to neutralization with 194 antibody #21(Figure 3D). Seventeen of the 33 (51.5%) mutations are located 195 between residues 437 and 508, which is the region of the RBD that physically 196 interacts with ACE2 (Singh et al., 2021) (Figure 3D and 3F, Figure S7A). Four 197 of the ten (40%) sensitive mutations are also located within the RBD interface (Figure 3D and 3F, Figure S7A). 198

199	Antibody #53 had 13 escape mutations of varying resistance, with 5
200	mutations (F456E, F486S, N487R, N501Y, Y505C) showing complete
201	resistance to neutralizing activity (Figure 3C and 3E). Seven (53.85%)
202	mutations are located within the interface of the RBD-ACE2 interaction (Figure
203	3E and 3G, Figure S7B). Interestingly, six (46.15%) sensitive mutations are not
204	located within the RBD-ACE2 interface (Figure 3E and 3G, Figure S7B), which
205	indicates that binding to non-RBD binding epitopes can also have
206	neutralization effects (Li et al., 2020; Prevost and Finzi, 2021).
207	
208	Heterogeneous reaction of serological NAbs to S variants in
209	convalescent COVID-19 patients
210	We next screened the serum from 25 COVID-19 patients who had recovered
211	from SARS-CoV-2 infection. Using hierarchical cluster analysis, the
212	convalescent patients clustered into three groups based on their NAb titers:
213	high, low, and mixed (Figure 4A and 4B). After determining the percentage of
214	escape mutations under three different EC50 thresholds (10, 30, 50), it was
215	observed that the number of escape mutations were fewer for the high-titer
216	NAb group than the low-titer NAb group (Figure 4C).
217	Next, the NAbs to wild-type and mutant S proteins were compared (Figure
218	4D). The D614G variant did not lead to a change of NAbs to S1 and S1+S2
219	proteins (Figure 4E, Figure S8). Using statistical analysis, the number of NAbs

221	escape mutations [K417N, G446V, F490L, K417N/E484K/N501Y (B.1.351
222	strain)] and 4 newly identified escape mutations (A372S, F456E, N487R,
223	Y505C) (Figure 4F and 4G) (Chen et al., 2021; Li et al., 2021; Li et al., 2020;
224	Zhou et al., 2021). Notably, structural analyses show that 5 escape mutations
225	(K417N/E484K/N501Y, G446V, F456E, N487R, F490L) are located within the
226	interface of RBD-ACE2 interaction, thus indicating that this RBD subdomain is
227	important in neutralizing SARS-CoV-2 infection (Wang et al., 2020). All these
228	results demonstrate the heterogeneous reactivity of NAbs produced by
229	COVID-19 patients across S variants.

230

231 Heterogeneous reactivity of NAbs produced by vaccinees to S variants

232 The mSAIS assay was next used to measure the neutralizing effect of antibodies produced by 30 vaccinees who received the inactivated vaccine in 233 234 China (Wu et al., 2021). NAbs were generated to the majority of S variants 235 (Figure 5A). Using hierarchical cluster analysis, the vaccinees consistently 236 clustered into two groups based on the level of their NAb titer: low and high (Figure 5A and 5B). Using three EC50 thresholds (10, 20, 30), high-titer NAb 237 238 group had a lower number of escape mutations compared to low-titer NAb 239 group (Figure 5C).

Next, the NAb titers of vaccinees across all S variants were ascertained (Figure 5D). Like the convalescent COVID-19 patients, the D614G variant did not alter the neutralizing effect of the NAbs compared to wild-type S1+S2, S2,

243	and RBD (Figure 5E, Figure S9). Using statistical analysis, four escape
244	mutations were identified, including 2 known (N501Y, K417N/E484K/N501Y)
245	and 2 new (K378N, P499R) mutations (Figure 5F and 5G) (Chen et al., 2021).
246	To validate the results obtained with the mSAIS assay, we analyzed the
247	NAbs with a SARS-CoV-2 pseudovirus neutralization assay displaying
248	wild-type and mutant S (wild-type, D614G, B.1.1.7, B.1.351, P.1). The results
249	for the D614G, B.1.1.7, B.1.351 variants aligned with the data obtained with
250	the mSAIS assay (Figure 5H). The vaccinees also separated into high- and
251	low-titer NAb groups (Figure 5I), further supporting the data obtained with the
252	mSAIS assay Figure 5C).

253

High titer of NAbs contain anti-Spike antibodies with diverse binding epitopes

256 Two recent studies with rhesus macaques have shown that a high titer of NAbs 257 produced in response to vaccination (DNA-based or adenovirus serotype 26 258 (Ad26) vector-based) provided good protection against infection when challenged with SARS-CoV-2 (Mercado et al., 2020; Yu et al., 2020). In 259 260 another study, NAb titers were significantly higher in vaccinees who had 261 COVID-19 previously than vaccinees who never had COVID-19. Moreover, the vaccinees who had been infected with SARS-CoV-2 possessed NAbs that 262 263 were able to neutralize all prevalent S variants (Stamatatos et al., 2021).

In order to provide insight into how well the high-titer NAb samples could protect against SARS-CoV-2 variants, we analyzed the differential expression of anti-S antibodies in the vaccinees. The level of antibodies that target the S protein's S1, S2 extracellular domain (ECD), and RBD is higher in the high-titer NAb group than the low-titer NAb group. Of these three antibodies, the differing level of anti-RBD antibodies across the two groups was the most pronounced (Figure 6A).

Next, we performed epitope mapping of the vaccinees' serological anti-S antibodies using a tiled peptide microarray representing the full-length S protein as previously described (Liang et al., 2021; Wang et al., 2020). Indeed, the results indicate that the high-titer NAb group bound to more diverse epitopes than the low-titer NAb group (Figure 6B). The number of immunogenic peptides within the S1, S2ECD, and RBD is also consistently higher in the high-titer NAb group (Figure 6C).

To further validate our findings, sera from the 104 vaccinees were 278 analyzed using a SARS-CoV-2 pseudovirus neutralization assay. Prior to data 279 280 analysis, all vaccinees were separated into three groups according to their 281 NAb titers (<10, 10-50, >50). Notably, the results show that the concentration 282 of anti-S antibodies is proportional to the concentration of NAbs. However, 283 there was no difference in the levels of anti-S1 antibodies that target the 284 N-terminus or C-terminus across the vaccinees. The levels of anti-S2 ECD antibodies were significantly different only between NAb titers of <10 and >50 285

(Figure 7A). These results demonstrate that the antibodies produced in
response to vaccination of inactivated vaccine primarily target the RBD (Figure
6A and 7A).

The peptide microarray was also employed to examine serological NAbs with a larger vaccinated cohort (n=104). The data confirm that the anti-S antibodies in the high-titer NAb group bind to more peptides representing the S1, S1 N-terminal domain, RBD, and S2 ECD of the S protein than the low-titer NAb group (Figure 7B, 7C). These data indicate that high NAb titers contain anti-S antibodies with increased binding diversity.

295

296 **Discussion**

The SARS-CoV-2 virus has mutated over time, resulting in circulating viral strains with altered transmission efficiencies, mortality rates, and S variants that can escape from the neutralizing effect of antibodies (Alam et al., 2021) (Davies et al., 2021; Hou et al., 2020b; Prevost and Finzi, 2021). Therefore, significant effort has been devoted to improve the diagnosis, prevention, and treatment of COVID-19 patients infected with SARS-CoV-2 variants (Abdool Karim and de Oliveira, 2021).

In this work, we developed an mSAIS assay that enables the detection of NAbs to numerous S variants simultaneously and rapidly. It has numerous advantages compared to the enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assays (Li et al., 2021; Tan et al., 2020;

308 Weisblum et al., 2020). First, our flexible platform can be easily adapted to 309 include new S variants as they emerge. Second, only a laser scanner capable 310 of detecting Cy5 is required to perform the mSAIS assay. Third, the 311 multiplexed nature of the platform significantly reduces the sample volume. 312 reagents, time, and cost to obtain data compared to single-plexed assays (Xu 313 et al., 2020). For example, only 20 µL of serum was needed to screen for NAbs 314 against 72 S variants in this study. In comparison, the volume requirements for 315 ELISA or the pseudovirus neutralization assay would be 1,440 (72×) or 3,240 316 (162×) µL, respectively.

317 Using the mSAIS assay, we compared purified mouse and rabbit 318 antibodies. Of the three antibodies tested, antibody #53 was able to inhibit the 319 S-ACE2 interaction across the most S variants, thus it is a superior candidate 320 for COVID-19 therapy. The comprehensive mapping of antibodies to different 321 S variants would be valuable in understanding the sensitivity of mutations to 322 antibody neutralization, and help develop antibody cocktails for COVID-19 therapy (Li et al., 2021; Li et al., 2020; Prevost and Finzi, 2021; Starr et al., 323 324 2021).

Using serum from convalescent COVID-19 patients and vaccinees with the mSAIS assay, we identified 4 and 2 new resistant mutations, respectively, that escape NAb recognition (Figures 4 and 5). We also show that there are fewer escape mutations in high NAb titers than low titers, and this was observed in both convalescent COVID-19 patients and vaccinees (Figures 4C

330 and 5C). Using a large cohort of 104 vaccinees with multiple assays (i.e., 331 mSAIS assay, peptide array, pseudovirus neutralization assay), we further 332 demonstrate that high titer NAbs contain anti-S antibodies that target more 333 diverse binding epitopes, thus leading to more neutralizing capacity across a 334 breadth of S variants (Figure 6 and 7). The production of heterogenous 335 antibodies could be due to the somatic mutations that occur during antibody 336 maturation (Muecksch et al., 2021). Finally, our data suggest that an effective 337 COVID-19 vaccination strategy to defend against the mutating SARS-CoV-2 is 338 to elicit the immune response to produce high-titer NAbs that contain a large 339 diversity of anti-S antibodies (Stamatatos et al., 2021; Starr. et al., 2021). 340 However, the association between NAb titer and its ability to protect against 341 SARS-CoV-2 infection in humans is unclear (Jin et al., 2021).

There were several limitations in this study. First, the mSAIS assay is *in vitro*, which might not accurately reflect results *in vivo*. Second, some conformational and glycosylation epitopes might not be detected using the peptide microarray that employed chemically-synthesized peptides (Wang et al., 2020). Finally, the number of serum samples from convalescent COVID-19 patients and vaccinees were limited. The results obtained in this study should be validated in a large different cohort in the future.

349

350 **Conclusion**

351 Altogether, we developed a high-throughput microarray-based mSAIS assay,

which enables the multiplexed and rapid screening of NAbs to SARS-CoV-2 S 352 353 variants. Using the mSAIS assay, we confirmed the neutralization capabilities 354 of NAbs to known mutations, identified a number of new mutations that are 355 resistant to the NAbs, and showed that there were fewer escape mutations 356 with high NAb titers than low NAb titers in both convalescent COVID-19 patients and vaccinees. The data demonstrate the great potential of our 357 proteomics platform in mapping the ability of NAbs to block the interaction 358 359 between SARS-CoV-2 S variants and ACE2 interactions. Although we tested 360 purified antibodies and serum in this study, the mSAIS assay could be used 361 with other sample types as well. Data gleaned from the mSAIS will help develop more effective vaccines and therapeutic antibodies to fight against 362 363 COVID-19.

364

365 **References**

- Abdool Karim, S.S., and de Oliveira, T. (2021). New SARS-CoV-2 Variants Clinical, Public Health,
- 367 and Vaccine Implications. N Engl J Med 384, 1866-1868.
- 368 Alam, I., Radovanovic, A., Incitti, R., Kamau, A.A., Alarawi, M., Azhar, E.I., and Gojobori, T. (2021).
- CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. Lancet Infect Dis
 21,602.
- Aschwanden, C. (2021). Five reasons why COVID herd immunity is probably impossible. Nature *591*,
 520-522.
- 373 Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.A., Esswein, S.R., Gristick, H.B., Malyutin, A.G., Sharaf,
- N.G., Huey-Tubman, K.E., Lee, Y.E., et al. (2020). SARS-CoV-2 neutralizing antibody structures inform
 therapeutic strategies. Nature 588, 682-687.
- Burki, T. (2021). Understanding variants of SARS-CoV-2. Lancet 397, 462.
- 377 Chen, R.E., Zhang, X., Case, J.B., Winkler, E.S., Liu, Y., VanBlargan, L.A., Liu, J., Errico, J.M., Xie, X.,
- 378 Suryadevara, N., et al. (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and
- 379 serum-derived polyclonal antibodies. Nat Med 27,717-726.
- 380 Collier, D.A., De Marco, A., Ferreira, I., Meng, B., Datir, R., Walls, A.C., Kemp, S.S., Bassi, J., Pinto, D.,
- 381 Fregni, C.S., et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

- 383 Dai, L., and Gao, G.F. (2021). Viral targets for vaccines against COVID-19. Nat Rev Immunol 21, 73-82.
- Davies, N.G., Jarvis, C.I., Group, C.C.-W., Edmunds, W.J., Jewell, N.P., Diaz-Ordaz, K., and Keogh, R.H.
- (2021). Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature
 593,270-274.
- 387 Del Rio, C., and Malani, P. (2021). COVID-19 in 2021-Continuing Uncertainty. JAMA 325,1389-1390.
- Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real
- time. Lancet Infect Dis 20, 533-534.
- 390 Galloway, S.E., Paul, P., MacCannell, D.R., Johansson, M.A., Brooks, J.T., MacNeil, A., Slayton, R.B., Tong,
- 391 S., Silk, B.J., Armstrong, G.L., et al. (2021). Emergence of SARS-CoV-2 B.1.1.7 Lineage United States,
- 392 December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep *70*, 95-99.
- 393 Garcia-Beltran, W.F., Lam, E.C., St Denis, K., Nitido, A.D., Garcia, Z.H., Hauser, B.M., Feldman, J.,
- Pavlovic, M.N., Gregory, D.J., Poznansky, M.C., *et al.* (2021). Multiple SARS-CoV-2 variants escape
 neutralization by vaccine-induced humoral immunity. Cell *184*,2372-2383.e9.
- 396 Hou, X., Zhang, X., Wu, X., Lu, M., Wang, D., Xu, M., Wang, H., Liang, T., Dai, J., Duan, H., et al. (2020a).
- Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage
 COVID-19 Infection. Mol Cell Proteomics *19*, 1749-1759.
- 399 Hou, Y.J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinnon, K.H., 3rd, Leist, S.R., Schafer, A.,
- 400 Nakajima, N., Takahashi, K., et al. (2020b). SARS-CoV-2 D614G variant exhibits efficient replication ex
 401 vivo and transmission in vivo. Science *370*, 1464-1468.
- Jin, P., Li, J., Pan, H., Wu, Y., and Zhu, F. (2021). Immunological surrogate endpoints of COVID-2019
 vaccines: the evidence we have versus the evidence we need. Signal Transduct Target Ther 6, 48.
- Kemp, S.A., Collier, D.A., Datir, R.P., Ferreira, I., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C.,
 Mlcochova, P., Lumb, I.U., *et al.* (2021). SARS-CoV-2 evolution during treatment of chronic infection.
 Nature *592*,277-282.
- Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi,
 E.E., Bhattacharya, T., Foley, B., *et al.* (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that
 D614G Increases Infectivity of the COVID-19 Virus. Cell *182*, 812-827 e819.
- Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., et al. (2021).
 SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. Cell
 184,2362-2371.e9.
- Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., *et al.* (2020). The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell *182*, 1284-1294 e1289.
- 416 Liang, T., Cheng, M., Teng, F., Wang, H., Deng, Y., Zhang, J., Qin, C., Guo, S., Zhao, H., and Yu, X. (2021).
- 417 Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and 418 neutralization. Signal Transduct Target Ther *6*, 166.
- 419 Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C.R., Swanson, K.A., Cai, H., Sarkar, R., Chen, W., Cutler,
- 420 M., et al. (2021). Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med 384,1466-1468.
- 421 Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K.,
- 422 Barnabas, S.L., Bhorat, Q.E., et al. (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against
- 423 the B.1.351 Variant. N Engl J Med, NEJMoa2102214.
- 424 Mercado, N.B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K.,
- 425 Tostanoski, L.H., et al. (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus

³⁸² Nature *593*,136-141.

426 macaques. Nature 586, 583-588.

- 427 Muecksch, F., Weisblum, Y., Barnes, C.O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J.C.C., Flyak, A.I.,
- 428 DeLaitsch, A.T., Huey-Tubman, K.E., Hou, S., et al. (2021). Development of potency, breadth and
- 429 resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv.
- 430 Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020).
- 431 Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. Nat Protoc 15,
 432 3699-3715.
- Prevost, J., and Finzi, A. (2021). The great escape? SARS-CoV-2 variants evading neutralizing responses.
 Cell Host Microbe 29, 322-324.
- 435 Priesemann, V., Balling, R., Brinkmann, M.M., Ciesek, S., Czypionka, T., Eckerle, I., Giordano, G., Hanson,
- 436 C., Hel, Z., Hotulainen, P., *et al.* (2021). An action plan for pan-European defence against new 437 SARS-CoV-2 variants. Lancet *397*, 469-470.
- 437 SARS-CoV-2 variants. Lancet *397*, 469-470.
 438 Singh, A., Steinkellner, G., Kochl, K., Gruber, K., and Gruber, C.C. (2021). Serine 477 plays a crucial role
- 439 in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. Sci Rep 11, 4320.
- 440 Stamatatos, L., Czartoski, J., Wan, Y.H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E.,
- 441 Jennewein, M.F., MacCamy, A.J., *et al.* (2021). mRNA vaccination boosts cross-variant neutralizing 442 antibodies elicited by SARS-CoV-2 infection. Science, eabg9175.
- 443 Starr, T.N., Greaney, A.J., Dingens, A.S., and Bloom, J.D. (2021). Complete map of SARS-CoV-2 RBD
- 444 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep445 Med 2,100255.
- Starr., T., Czudnochowski., N., Zatta., F., Park., Y., Veesler., D., Corti., D., Bloom., J., and Snell., G. (2021).
 Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral
 escape. bioRxiv.
- 449 Tan, C.W., Chia, W.N., Qin, X., Liu, P., Chen, M.I., Tiu, C., Hu, Z., Chen, V.C., Young, B.E., Sia, W.R., et al.
- 450 (2020). A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of 451 ACE2-spike protein-protein interaction. Nat Biotechnol *38*, 1073-1078.
- 452 Wang, H., Wu, X., Zhang, X., Hou, X., Liang, T., Wang, D., Teng, F., Dai, J., Duan, H., Guo, S., et al. (2020).
- 453 SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid 454 Resolution. ACS Cent Sci *6*, 2238-2249.
- Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D., *et al.*(2021a). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature *593*,130-135.
- Wang, P., Wang, M., Yu, J., Cerutti, G., Nair, M.S., Huang, Y., Kwong, P.D., Shapiro, L., and Ho, D.D.
 (2021b). Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv.
- 459 Wang., H., Hou., X., Zhang., X., Wu., X., Liang., T., Wang., D., Teng., F., Dai., J., Duan., H., Guo., S., et al.
- 460 (2020). SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid
- 461 resolution. ACS Cent Sci 6,2238-2249.
- Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F., Rutkowska, M.,
 Hoffmann, H.H., Michailidis, E., *et al.* (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike
 protein variants. Elife *9*,e61312.
- Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E.,
 de Oliveira, T., Vermeulen, M., van der Berg, K., *et al.* (2021). SARS-CoV-2 501Y.V2 escapes
 neutralization by South African COVID-19 donor plasma. Nat Med *27*,622-625..
- 468 Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., et al. (2021). Safety,
- 469 tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults

- 470 aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
- 471 Lancet Infect Dis,S1473-3099(20)30987-7.
- 472 Xu, M., Deng, J., Xu, K., Zhu, T., Han, L., Yan, Y., Yao, D., Deng, H., Wang, D., Sun, Y., et al. (2019).
- 473 In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional
 474 Chinese medicine. Theranostics *9*, 2475-2488.
- 475 Xu, M., Wang, D., Wang, H., Zhang, X., Liang, T., Zhang, K., Zhang, J., Xu, D., and Yu, X. (2020).
- 476 COVID-19 diagnostic testing: Technology perspective. Clin Transl Med, e158.
- 477 Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nkolola, J.P., Liu, J., Li,
- Z., Chandrashekar, A., et al. (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
 Science 369, 806-811.
- Zhang, L., Jackson, C.B., Mou, H., Ojha, A., Peng, H., Quinlan, B.D., Rangarajan, E.S., Pan, A.,
 Vanderheiden, A., Suthar, M.S., *et al.* (2020a). SARS-CoV-2 spike-protein D614G mutation increases
 virion spike density and infectivity. Nat Commun *11*, 6013.
- 483 Zhang, N.N., Li, X.F., Deng, Y.Q., Zhao, H., Huang, Y.J., Yang, G., Huang, W.J., Gao, P., Zhou, C., Zhang,
- 484 R.R., et al. (2020b). A Thermostable mRNA Vaccine against COVID-19. Cell 182, 1271-1283 e1216.
- 485 Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E.,
- Tuekprakhon, A., Nutalai, R., et al. (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from
 natural and vaccine-induced sera. Cell 184,2348-2361.

488

489 **Contributions**

- J.Z. and L.X. provided the purified spike variant proteins. M. Z., S. Y., C. H., Y.
- 491 H., and Y. W. provided the clinical samples. X. Z., H. W., J. Z., J. R., H. B., and
- 492 X. Y. executed microarray experiments. X. Z., T. L., H. P., S. L., C.W., and X.Y.
- 493 executed the bioinformatics and statistical analyses. J.V. executed the
- 494 pseudovirus based neutralization assay. H. Z., M. L., X. H., and B. K. executed
- the authentic virus-based neutralization assay. X.Y., Y. W., and B. K. conceived
- the idea, designed experiments, analyzed the data, and wrote the manuscript.

497

498 Acknowledgement

499 This work was supported by the National Natural Science Foundation of China

500 (31870823), National Key R&D Program of China (2020YFE0202200), State

501	Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201904,
502	SKLP-O201703, SKLP-O202007), the National Program on Key Basic
503	Research Project (2018YFA0507503, 2017YFC0906703, 2018ZX09733003)
504	and the Beijing Municipal Education Commission, Beijing Municipal Natural
505	Science Foundation (M21003) and Beijing Municipal Science & Technology
506	Commission (Z201100001020001; Z201100005420022). We thank Dr.
507	Brianne Petritis for her critical review and editing of this manuscript.
508	

509 **Competing interests**

- 510 None declared.
- 511

512 Supplemental information

- 513 The supplemental information includes 3 supplementary tables and 9 514 supplementary figures.
- 515

516 **Figures and legends**

- 517 Figure 1. Development of the mSAIS assay. (A) A schematic illustration of
- the microarray-based mSAIS assay and potential biomedical applications; (B,
- 519 C) Intra- and inter-array reproducibility of the mSAIS assay in the absence and
- 520 presence of neutralizing antibodies, respectively.

521

522 Figure 2. SARS-CoV-2 S-ACE2 interaction mapping across different S

523 variants using the mSAIS assay. (A) Detection of different concentrations of ACE2 binding to S variants immobilized on the array. (B) Distribution of 524 525 S-ACE2 binding affinities (EC50) across different SARS-CoV-2 S variants. (C) 526 Fold changes of binding affinity between the wild-type and mutated S proteins. 527 The x-axis represents the S variants and the y-axis represents the log2 transformed IC50 ratio between the wild-type and mutated S proteins. (D) are 528 the dynamic curves representing S variants that bind to ACE2 with significantly 529 530 decreased binding affinity compared to the wild-type S protein. (E) Structural 531 analysis of escape mutations on the RBD (gray color) that interacts with ACE2 532 (green color). RBD mutations (PDB ID: 6M0J) are labelled in red.

533

534 Figure 3. Heterogeneous responses of purified antibodies to 535 **SARS-CoV-2 mutations.** (A-C) Distribution of neutralization activity (IC50) of 536 purified antibodies #73, #21 and #53 to the S variants, respectively. The x-axis represents the S variants and the y-axis represents the neutralization activity 537 (IC50) of the monoclonal antibody to each spike variant. (D, E) Fold changes 538 539 of the neutralization activity (IC50) of antibodies #21 and #53 between the 540 wild-type and mutant S proteins, respectively. The x-axis represents the S 541 variants and the y-axis represents the log2 transformed IC50 ratio between the 542 wild-type and mutated S proteins. (F, G) Structural analysis of the mutations 543 that decrease and increase the neutralization activity of antibodies #21 and 544 #53, respectively.

545

546	Figure 4. Heterogeneous responses of serological NAbs to SARS-CoV-2
547	S mutations in convalescent COVID-19 patients. (A) Hierarchical cluster
548	analysis of NAbs to S variants in convalescent COVID-19 patients. The
549	rainbow color from white to red correspond to the NAb titer from low to high,
550	respectively. (B) EC50 comparison of convalescent COVID-19 patients with
551	high and low NAb titers. (C) Comparison of escape mutations between
552	convalescent COVID-19 patients with high and low NAb titers with EC50
553	thresholds set at 10, 30 and 50, respectively. (D) Distribution of serological
554	NAbs to different SARS-CoV-2 S variants in convalescent COVID-19 patients.
555	(E) Comparison of NAbs between the wild-type and D614G S proteins. (F)
556	Comparison of NAbs between the wild-type S protein and S variants with
557	known escape mutations. (G) Comparison of NAbs between the wild-type S
558	protein and S variants with newly identified escape mutations. Significant
559	escape mutations were identified using an unpaired t test with a p value of
560	0.05.

561

Figure 5. Heterogeneous responses of serological NAbs to the SARS-CoV-2 S mutations in vaccinated individuals. (A) Hierarchical cluster analysis of NAbs to S variants in vaccinees. The rainbow color from white to red correspond the NAb titers from low to high, respectively. (B) EC50 comparison of vaccinees with high and low NAb titers. (C) Comparison of

567 escape mutations between vaccinees with high and low NAb titers with EC50 568 thresholds set at 10, 20 and 30, respectively. (D) Distribution of serological 569 NAbs to different SARS-CoV-2 S variants in vaccinees. (E) Comparison of NAbs between the wild-type and D614G S proteins. (F) Comparison of NAbs 570 571 between the wild-type S protein and S variants with known escape mutations. 572 (G) Comparison of NAbs between the wild-type S protein and S variants with newly-identified escape mutations. Significant escape mutations were 573 574 identified using an unpaired t test with a p-value of 0.05. (H) Detection of 575 serological NAbs to prevalent SARS-CoV-2 variants in the vaccinees using the pseudovirus neutralization assay. (I) Hierarchical cluster analysis of the NAbs 576 577 to prevalent SARS-CoV-2 variants in vaccinees. The rainbow color from white 578 to red correspond the NAb titers from low to high, respectively.

579

Figure 6. The NAb titer is associated with the diversity of anti-S antibodies in the serum of vaccinees. (A) A comparison of levels of antibodies that target the S1, RBD and S2 ECD. (B) Identification of vaccine-induced humoral immune responses to the S protein. (C) Association between the number of immunogenic peptides and NAb titers. A p-value (p) < 0.05 by Mann-Whitney test was considered to be significant. NTD = N-terminal domain

587

588 Figure 7. Validation of anti-S antibody diversity in 104 vaccinees. (A) A

589 comparison of levels of antibodies that target the S proteins and its domains.

- (B) Landscape of vaccine-induced humoral immune responses to the S protein.
- 591 (C) Association between the number of immunogenic peptides and NAb titers.
- 592 A p-value (p) < 0.05 by Mann-Whitney test was considered to be significant.
- 593 CTD = C-terminal domain; NTD = N-terminal domain. The NAb titers (ND50)
- ⁵⁹⁴ was measured using pseudovirus neutralization assay.

595

596 Materials and methods

597 **Collection of patient samples**

598 Clinical specimens were obtained from the Department of Clinical Laboratory 599 in Beijing Ditan Hospital, Capital Medical University (Beijing, China). Whole 600 blood was collected in a vacutainer tube, and centrifuged at 4,000×g at room 601 temperature (RT) for 10 minutes to separate serum. Serum was then 602 transferred to a clean tube and stored at -80° C until use. For safety purposes, serum collected from convalescent COVID-19 patients was inactivated at 56°C 603 604 for 30 minutes prior to any further sample processing. Notably, serum from 605 COVID-19 vaccinated individuals was obtained from healthy hospital staff 4 606 weeks after receiving the second vaccine dose, and convalescent samples 607 were collected from COVID-19 patients 2 to 4 weeks post discharge. Our 608 research was approved by the Ethics Committee of Beijing Ditan Hospital (No. 609 2021-010-01), and exemption of informed consent was obtained prior to sera collection. 610

611

612 Expression and purification of recombinant proteins for use on the 613 mSAIS assay

The DNA sequence encoding the SARS-CoV-2 Spike protein (S1+S2 ECD) 614 (YP_009724390.1) (Val 16-Pro1213), S1 Subunit (YP_009724390.1) 615 616 (Val16-Arg685), RBD (YP_009724390.1) (Arg319-Phe541) or variants were expressed with a polyhistidine tag at the C-terminus. The generation of 617 618 variants using site-directed mutagenesis was performed as previously 619 described (Li et al., 2020). In addition, two negative controls [SARS-CoV-2 Nucleocapsid (N), MERS-CoV-2 Spike RBD], one positive control 620 621 (SARS-CoV-2 wild-type RBD), and the extracellular domain of ACE2 were expressed with a polyhistidine tag at the C-terminus. The proteins were 622 expressed in HEK293 cells, followed by further purification on a Ni-NTA spin 623 624 column (Thermo Fisher). Protein purity was confirmed using an SDS-PAGE gel 625 stained with Coomassie blue.

626

627 Preparation of the mSAIS microarray

All purified proteins were diluted to 100 μg/mL and printed onto a
three-dimensional (3D)-modified slide surface (Capital Biochip Corp, Beijing,
China) in parallel and in duplicate using an Arrayjet microarrayer (Roslin, UK)
as previously described (Hou et al., 2020a; Wang et al., 2020; Xu et al., 2019).
The protein microarrays were stored at -20 °C until ready to use.

633

634 **Detection of NAbs using the mSAIS assay**

635	Prior to antibody detection, the protein microarrays were assembled in an
636	incubation tray and blocked with 1% (w/v) milk in 1x phosphate buffered saline,
637	pH 7.2 (PBS), with 0.2% (v/v) Tween-20 (PBST) for 10 min at room
638	temperature. After washing with PBST three times, the array was incubated
639	with serum diluted 10- to 320-fold in PBST for 30 min at room temperature.
640	After washing again, the array was then incubated for 60 min with Cy5-labeled
641	ACE2 (50 ng/mL). Finally, the array was washed with PBST and water,
642	dissembled from the tray, and dried via centrifugation for 2 min at 2,000 rpm.
643	The array was scanned with a GenePix 4300A microarray scanner (Molecular
644	Devices, Sunnyvale, CA, USA) at a 10 μm resolution using a laser at 635 nm
645	with 100% power/ PMT Gain 900. The median fluorescent signal intensity with
646	background subtraction was extracted using GenePix Pro7 software
647	(Molecular Devices, Sunnyvale, CA, USA).

648

649 SARS-CoV-2 pseudovirus neutralization assay

The SARS-CoV-2 pseudovirus neutralization assay was performed as previously described (Nie et al., 2020). Briefly, human sera were diluted using 3-fold serial dilutions with a starting concentration of 1:10 (two per dilution). The diluted sera were added into 96-well plates in duplicate, followed by the SARS-CoV-2 pseudovirus at a concentration of 1300 median tissue culture

infective dose (TCID50/mL). The sera and pseudovirus were incubated together at 37°C for 1 hour, and then monkey Vero cells were added at $2*10^{4}$ cells/100 mL cells per well. The plates were incubated at 37°C in a humidified atmosphere with 5% CO₂ for 24 hours before chemiluminescence detection was performed. The Reed-Muench method was used to calculate the neutralization titer.

661

662 Live SARS-CoV-2 neutralization assay

663 A suspension of Vero cells suspension was prepared at a cell density of 2×10⁵/ml. Serum samples were diluted 4-fold in cell culture medium and 664 665 inactivated at 56°C for 30 minutes. The inactivated serum was serially diluted 666 2-fold with MEM medium, followed by the addition of cell culture medium 667 containing 100 times the cell culture infective dose 50% (CCID50) of wild-type 668 SARS-CoV-2 virus. The mixture was placed into a 96-well plate and incubated at 37°C for 2 h in CO₂ 5%, and then $2 \Box \times \Box 10^4$ Vero cells were added and 669 670 incubated again at 37°C. The samples were microscopically examined for 671 cytopathic effect (CPE) after 7 days. The highest dilution of serum that showed 672 complete inhibition activity of SARS-CoV-2 was recorded as the neutralizing 673 antibody titer (ID50). Assays were performed in duplicate with negative control 674 serum.

The ID50 was calculated as: LogCCID50 = Xm + $1/2d - d \sum pi/100$, where Xm is the log10 of maximum dilution of the virus, the d is the logarithm of the

dilution fold, and \sum pi is the sum of the percentage of the cytopathic effect per dilution.

679

680 Detection of SARS-CoV-2 serum antibodies using a SARS-CoV-2

681 proteome peptide microarray

The peptide microarray containing truncated S proteins, and tiled peptides 682 representing SARS-CoV-2 S protein was prepared as our previous work (Liang 683 684 et al., 2021; Wang. et al., 2020). The array was assembled in an incubation 685 tray and blocked with 5% (w/v) milk in phosphate-buffered saline (PBS) 686 containing 0.05% (v/v) Tween-20 (PBST) for 30 min at room temperature 687 before antibody detection. After aspirating the blocking solution, the 1:200 688 diluted serum was added to the array and incubated at room temperature for 689 20 min. After washing three times with PBST, the array was then incubated for 690 20 min with a Cy3 labelled donkey anti-human IgG(H+L) antibody (Jackson 691 ImmunoResearch, USA) (2 µg/mL). Finally, the array was washed with PBST 692 and deionized water, disassembled from the tray and dried with vacuum pump. 693 The slide was scanned at 532 nm using a GenePix 4300A microarray scanner 694 (Molecular Devices, Sunnyvale, CA, USA). The median fluorescent signal 695 intensity of each spot with background subtraction was extracted using 696 GenePix Pro7 software (Molecular Devices, Sunnyvale, CA, USA).

697

698 **Data analysis**

699	The ability of the serological NAbs to inhibit the S-ACE2 interactions across
700	the different S variants was visualized as a heatmap using the MultiExperiment
701	Viewer software version 4.9 (Chu et al., 2008). Statistical analyses were
702	performed using the GraphPad Prism software 8.3 and Microsoft Excel with
703	the unpaired t test and Mann-Whitney test. A p-value (p) < 0.05 was
704	considered to be significant. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001.
705	The 3D structure of the SARS-CoV-2 RBD and ACE2 complex (PDB ID code:
706	6M0J) was visualized using the VMD 1.9.3, and mutations were annotated.













